文献速递技术与安全头颈PETCT

无需量化的抵抗:将定性FDG-PET/CT肿瘤反应评估标准融入日常实践

RESISTing the Need to Quantify: Putting Qualitative FDG-PET/CT Tumor Response Assessment Criteria into Daily Practice.
PubMed 文献 · AJNR Am J Neuroradiol · 2019-11-28

肿瘤反应评估对评价癌症疗效和预测生存至关重要,FDG-PET/CT的进展催生了利用代谢成像的肿瘤反应标准。本文回顾从CT和PET/CT定量及半定量系统向PET/CT定性系统的演变,介绍Lugano分类、Hopkins标准和头颈癌Neck Imaging Reporting and Data Systems标准,并通过示例病例说明如何在日常实践中使用这些快速、强大的定性PET/CT系统。

要点

  • 定性PET/CT评估标准易于临床应用、可重复性好,并能获得良好的预后结果。
  • 比较基线PET/CT与中期或治疗结束PET/CT,可将肿瘤反应分为完全代谢反应、部分代谢反应、无代谢反应或疾病进展。
  • 本文介绍Lugano淋巴瘤分类、Hopkins标准和头颈癌Neck Imaging Reporting and Data Systems三种定性标准。

核心结论

  • 定性PET/CT肿瘤反应评估标准(Lugano分类、Hopkins标准、Neck Imaging Reporting and Data Systems标准)快速、强大且易于在日常实践中应用,肿瘤反应分类对指导后续癌症管理和长期预后具有重要意义。

研究设计与样本

  • 综述文章,回顾肿瘤反应评估从CT和PET/CT定量及半定量系统向PET/CT定性系统的演变,介绍三种定性分类标准,并通过示例病例说明其日常实践应用;原文未报告检索范围与纳入文献数量。

诊断标准与关键数值

  • 定性PET/CT评估可将肿瘤反应分类为完全代谢反应、部分代谢反应、无代谢反应或疾病进展。
  • Lugano分类用于淋巴瘤的定性PET/CT肿瘤反应评估。
  • Hopkins标准用于定性PET/CT肿瘤反应评估。
  • Neck Imaging Reporting and Data Systems标准用于头颈癌的定性PET/CT肿瘤反应评估。

临床应用与阅片要点

  • 比较基线PET/CT与中期或治疗结束PET/CT,按定性标准将肿瘤反应分类为完全代谢反应、部分代谢反应、无代谢反应或疾病进展。
  • 定性PET/CT评估标准易于临床应用、可重复性好,并能获得良好的预后结果。
  • 肿瘤反应分类对指导后续癌症管理和长期患者预后具有重要意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Tumor response assessments are essential to evaluate cancer treatment efficacy and prognosticate survival in patients with cancer. Response criteria have evolved over multiple decades, including many imaging modalities and measurement schema. Advances in FDG-PET/CT have led to tumor response criteria that harness the power of metabolic imaging. Qualitative PET/CT assessment schema are easy to apply clinically, are reproducible, and yield good prognostic results. We present 3 such criteria, namely, the Lugano classification for lymphoma, the Hopkins criteria, and the Neck Imaging Reporting and Data Systems criteria for head and neck cancers. When comparing baseline PET/CTs with interim or end-of-treatment PET/CTs, radiologists can classify the tumor response as complete metabolic response, partial metabolic response, no metabolic response, or progressive disease, which has important implications in directing further cancer management and long-term patient prognosis. The purpose of this article is to review the progression of tumor response assessments from CT- and PET/CT-based quantitative and semi-quantitative systems to PET/CT-based qualitative systems; introduce the classification schema for these systems; and describe how to use these rapid, powerful, and qualitative PET/CT-based systems in daily practice through illustrative cases.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Peacock JG, Christensen CT, Banks KP, et al. RESISTing the Need to Quantify: Putting Qualitative FDG-PET/CT Tumor Response Assessment Criteria into Daily Practice. AJNR Am J Neuroradiol. 2019. PMID: 31780460. doi:10.3174/ajnr.A6294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。